Phase II Iressa & Carbo/Gem in NSCLC

• Status: Completed
• Trial end date: 2008-06-01

Summary

The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.

• Phase: Phase 2

Details

• Lead Sponsor: AstraZeneca
• Treatments: Carboplatin; Gefitinib; Gemcitabine